Project Grant R01AI192603
Award Date 8/10/26
Completion Date 7/31/31
Dollars Obligated $826K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pleasanton, CA 94588, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Washington $264,750 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate local B cell immune response to varicella zoster virus infection in shingles patients. The research examines antibody-secreting cells present in shingles lesions, focusing on characterizing virus-specific human monoclonal antibodies derived from tissue biopsies. Prior single-cell RNA...
- The National Institute on Aging awarded Kaiser Foundation Hospitals $825,851 on August 15, 2026, under the Aging Research program (CFDA 93.866) to investigate bi-directional associations between periodontitis, periodontal treatment, and Alzheimer's disease and related dementias in an integrated health system. The project will link detailed dental and medical electronic health records from over 80,000 Kaiser Permanente Northwest members to evaluate whether moderate or severe periodontitis is...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $211,008 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate neutralizing and Fc-receptor-mediated antibody functions in controlling human herpesvirus-8 (HHV-8) infection. The research addresses Kaposi's sarcoma, an AIDS-associated malignancy driven by KSHV that emerges in immunocompromised populations including people living with HIV and solid organ transplant...
- The National Institute of Allergy and Infectious Diseases awarded Fred Hutchinson Cancer Center $238,899 on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical evaluation of human monoclonal antibodies for herpes simplex virus type 2 (HSV-2) therapeutics. The research isolates and characterizes antibody-secreting cells discovered in genital skin tissue up to four months following HSV lesion healing. The project involves comprehensive...
- The National Cancer Institute awarded Kaiser Foundation Hospitals $613,229 on August 26, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to advance evidence on treatment decisions for low-risk prostate cancer in the United States. Kaiser Permanente's Kaiser Foundation Research Institute, operating at its Pleasanton, California location, will conduct two parallel cohort studies evaluating long-term clinical outcomes and patient-reported outcomes associated with active...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded a cooperative agreement to the University of Maryland, Baltimore for $2,347,868 on September 20, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a prospective human clinical trial investigating the molecular determinants of durable versus transient antibody responses following vaccination. The...
- The National Institute of Allergy and Infectious Diseases awarded The Leland Stanford Junior University $246,881 on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine cryo-electron microscopy (cryo-EM) structures of varicella-zoster virus glycoprotein complexes in native membranes. The research leverages cyclapol-based membrane extraction and single-particle cryo-EM to resolve near-atomic resolution structures of VZV glycoprotein complexes...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $231,000 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify, characterize, and develop human monoclonal antibodies whose primary protective mechanism is antibody-dependent cellular cytotoxicity (ADCC) for treatment and prevention of genital, neonatal, and recurrent herpes simplex virus (HSV) infections. The research builds on preclinical mouse...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, Los Angeles $673,177 on August 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate hepatitis B infection risk in persons with HIV transitioning to long-acting antiretroviral therapy (LA-ART). The project, LANCET-HBV, addresses a critical gap in clinical knowledge: current LA-ART regimens lack activity against hepatitis B virus, creating vulnerability for...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $120,312 to the University of California, Berkeley on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into adenosine deaminases acting on RNA (ADARs), enzymes that edit RNA to regulate gene expression and immune responses. The research aims to identify viral and host...